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Abstract
Background: Myopathy and exercise intolerance are prominent clinical features in carriers of a point-mutation or
large-scale deletion in the mitochondrial DNA (mtDNA). In the majority of patients, the mtDNA mutation is
heteroplasmic with varying mutation loads between tissues of an individual. Exercise-induced muscle regeneration
has been shown to be beneficial in some mtDNA mutation carriers, but is often not feasible for this patient group.
In this study, we performed in vitro analysis of mesoangioblasts from mtDNA mutation carriers to assess their
potential to be used as source for autologous myogenic cell therapy.
Methods: We assessed the heteroplasmy level of patient-derived mesoangioblasts, isolated from skeletal muscle of
multiple carriers of different mtDNA point-mutations (n = 25). Mesoangioblast cultures with < 10% mtDNA mutation
were further analyzed with respect to immunophenotype, proliferation capacity, in vitro myogenic differentiation
potential, mitochondrial function, and mtDNA quantity.
Results: This study demonstrated that mesoangioblasts in half of the patients contained no or a very low mutation
load (< 10%), despite a much higher mutation load in their skeletal muscle. Moreover, none of the large-scale
mtDNA deletion carriers displayed the deletion in mesoangioblasts, despite high percentages in skeletal muscle.
The mesoangioblasts with no or a very low mutation load (< 10%) displayed normal mitochondrial function,
proliferative capacity, and myogenic differentiation capacity.
Conclusions: Our data demonstrates that in half of the mtDNA mutation carriers, their mesoangioblasts are (nearly)
mutation free and can potentially be used as source for autologous cell therapy for generation of new muscle
fibers without mtDNA mutation and normal mitochondrial function.
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Introduction
Mitochondria generate the bulk of cellular energy (ATP),
and each mitochondrion contains multiple copies of mito-
chondrial DNA (mtDNA). Together with nuclear-encoded
proteins, the mtDNA encodes the subunits of the ATP-
generating oxidative phosphorylation (OXPHOS) system.
Pathogenic heteroplasmic (mixture wild-type/mutant
mtDNA) mtDNA mutations can cause OXPHOS dysfunc-
tion and severe multisystem disorders (frequency 1/5000)
[1]. High-energy-requiring tissues like muscle and brain
are most severely affected. Progressive myopathy and ex-
ercise intolerance occur in > 50% of mtDNA mutation
carriers, and aging appears to play a major role as well,
since the percentage of myopathy patients drastically in-
creases with age [2, 3], making these the most debilitating
symptoms for these patients [4].
One of the most common mtDNA mutations giving
rise to myopathy, either isolated or as part of a clinical
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spectrum, is the m.3243A>G mutation in the dihydrouri-
dine loop of mitochondrial tRNA Leu (UUR) [5]. But
also other tRNA Leu point-mutations, as well as muta-
tions in protein-encoding and in other tRNA genes, have
been observed in patients with mitochondrial myopathy
[2, 3]. These mutations are generally heteroplasmic, and
large differences in mutation load between tissues were
seen. Post-mitotic tissues, such as skeletal muscle, gener-
ally possess the highest mutation load. In addition to
variability between tissues, the mutation load can also
vary in time or between muscle fibers of a single skeletal
muscle [3, 6]. If the mutation load exceeds a certain
tissue-specific threshold, the mitochondrial oxidative
phosphorylation (OXPHOS) system will become defi-
cient, resulting in diminished oxidative capacity and
pathology leading to clinical symptoms.
One of the key problems for mtDNA patients is the
lack of effective therapy. No pharmaceutical drugs have
been shown to treat mtDNA diseases effectively in clin-
ical trials [7]. Alternatively, physical exercise has shown
some success in inducing muscle regeneration and im-
proving OXPHOS capacity, but this is seriously ham-
pered by the exercise intolerance and exercise-induced
lactate increase in mtDNA mutation carriers and pa-
tients. Both resistance and endurance exercise protocols
have been applied in mtDNA patients [8, 9]. In contrast
to endurance exercise that predominantly induces mito-
chondrial biogenesis, resistance type exercise increases
muscle mass by inducing regeneration through prolifera-
tion and differentiation of myogenic precursors like sat-
ellite cells and other stem cells [10–12]. Satellite cells
are regarded as the major myogenic precursors and in
carriers of the sporadic m.12315G>A or m.12320A>G
mutation, they have been shown to be nearly all homo-
plasmic wild-type despite a high mutation load of 94% in
skeletal muscle. Moreover, induction of muscle regener-
ation following muscle damage demonstrated to trigger
generation of nearly all homoplasmic wild-type COX-
positive muscle fibers in these persons [13–15]. Large-
scale mtDNA deletions are lost during satellite cell to
myoblast transition in a number of CPEO patients with
> 3 kb mtDNA deletions and mutation load in skeletal
muscle varying between 10 and 67% [16]. However, the
therapeutic potential of satellite cells is hampered by
their poor ex vivo proliferation capacity and requirement
for intra-muscular delivery [17].
In recent years, other types of stem cells with myogenic
potential have been identified [18], one being pericytes, also
called mesoangioblasts (MABs), which are mesoderm-
derived (CD13+/CD44+/NG2+) stem cells that lie under-
neath the basal lamina of the small vessels of muscle fibers
[19, 20]. Since there is no specific MAB marker, they are
characterized based on a combination of markers. MABs
have high myogenic potential (20–40%) and induce muscle
regeneration either directly by fusion with damaged mus-
cles or by contributing to the satellite cell pool [21]. More-
over, they can be efficiently expanded ex vivo; MABs
express multiple growth factors and ß2 and α4 integrins,
which are proteins used by leukocytes to adhere and cross
the endothelium, allowing systemically intra-arterial admin-
istration [17, 22, 23]. Muscle regeneration by systemic in-
jection of allogeneic MABs has been reported to induce
muscle regeneration and partly compensation for the defect
in mice and dog models of Duchenne muscular dystrophy
(DMD) [22, 24]. The success of MAB transplantation in
animal models with respect to safety, proliferative capacity,
and myogenic potential has led to a phase I/II clinical trial
with donor MABs for DMD [25], which showed that the
method was feasible and relatively safe. The drawback of an
allogeneic cell therapy is the requirement for immunosup-
pression, which would be circumvented by using autolo-
gous MABs. Because of the therapeutic potential of MABs
in myogenic stem cell therapy and the identification of sat-
ellite cells and myoblast clones with low/absent mtDNA
mutation load in mtDNA mutation carriers [14, 16, 26], we
assessed if MABs from carriers of a maternally inherited
mtDNA point-mutation or a sporadic mtDNA deletion
could potentially be used for autologous cell therapy.
Materials and methods
Study design
Participants of this explorative study enrolled at the study
site Erasmus MC (NL). All individuals underwent a vastus
lateralis muscle biopsy under local anesthesia for other
(diagnostic) analyses. Written informed consent was ob-
tained from all participants, and this study was approved
by the medical ethical committee of the Erasmus MC,
The Netherlands. A total of 13 carriers of a heteroplasmic
tRNA Leu mutation in the mtDNA were included: 9
m.3243A>G carriers, 2 persons (mother and daughter)
with a m.3271 T>C mutation, and 2 persons (mother and
daughter) with a m.3291 T>C mutation. For the hetero-
plasmic m.11778G>A mutation in the MT-ND4 gene, 2
siblings were included. For the heteroplasmic m.8363G>A
mutation in tRNA Lys, 4 cousins were included. Clinical
characteristics of the individuals are shown in Table 1.
The point-mutations were all maternally inherited. Het-
eroplasmic large-scale deletions were observed in 6
chronic progressive external ophthalmoplegia (CPEO) pa-
tients. These were sporadic and POLG mutations were ex-
cluded. POLG sequence analysis and patient verification
were performed according to clinical diagnostic standards
(data not shown). The phenotypic characteristics of all
participants are presented in Table 1.
Mesoangioblast isolation and culture
The muscle fragment was collected in mesoangioblast culture
medium: IMDM medium containing 10%FBS (Bodinco),
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0.1% gentamycin, 1X glutamine, 1X sodium pyruvate, 0.2% 2-
mercapto ethanol, 1x Insulin-Transferrin-Selenium, 1X Non-
Essential Amino Acids, and 5 ng/ml human FGF-2 (Miltenyi
Biotec). All materials were obtained from Thermo Scientific,
unless stated otherwise. Mesoangioblasts from a vastus latera-
lis skeletal muscle biopsy were isolated and cultured as de-
scribed before [27]. In brief, skeletal muscle biopsies were
rinsed with PBS, cut in small fragments, and plated on a
type I collagen-coated dish with a few drops of the afore-
mentioned medium. From the muscle biopsy, fibroblasts
spread out while mesoangioblasts poorly adhere to these
fibroblasts. After 10–14 days during which medium was
regularly added, the medium containing mesoangioblasts
was transferred to a new dish (5000/cm2) and MABs were
cultured as attaching cells. Alternatively, outgrowth of the
muscle biopsies was trypsinized after 10–14 days and
seeded to a new dish at a 10,000 cells/cm2. The following
2 days, the medium containing mesoangioblasts was trans-
ferred to a new dish (5000/cm2) and MABs were further
cultured as attaching cells.
Mesoangioblast characterization and single-cell collection
Alkaline phosphatase-positive cells were collected via sort-
ing using PE-labeled anti-alkaline phosphatase (R&D) as
Table 1 Clinical and molecular characteristics mtDNA mutation carriers
Patient
ID
Age Sex mtDNA mutation % sk.
muscle
%
MABS
Clinical features
M1a 37 M tRNA Lys
m.8363G>A
46 < 1 Mild EI, cephalia
M8a 40 F 51 6.0 EI, ataxia, dysarthria
M18a 35 F 87 78 Spinocerebellar ataxia with dysarthria
M20a 47 F 90 82 EI, axonal polyneuropathy, dysarthria
M5b 27 F tRNA Leu
m.3243A>G
40 9.4 EI, restless legs, cephalia (migraine like)
M6b 21 M 93 3.4 MELAS, bradyphrenia, mental deterioration
M9c 59 F 15 1.6 DM, hearing loss, cerebellar ataxia, slight mental deterioration
M10c 33 F 28 < 1 Discrete cerebellar ataxia
M132 61 F 62 9.1 Cerebellar ataxia, hemianopsia, CVA hemiparesis right, motor aphasia, DM, EI,
seizures
M133 38 F 73 5.5 DM, hearing aid, CMP, EI, migraine-like headaches, proximal weakness, reactive
depression
M137 58 M 80 22 Deafness, EI, CVA, PNP, DM, hypertension, Dupuytren
M19 43 F 79 64 MIDD, anorexia
M32 40 M 80 67 MIDD, nephropathy, myopathy, HCM
M2 22 F tRNA Leu
m.3271 T>C
100 96 Myopathy, EI
M22e 51 F 73 41 Headaches
M11d 11 F tRNA Leu
m.3291 T>C
94 73 EI, CMP, myopathy
M17d 34 F 62 1.6 EI, hearing loss, mental retardation
M34 f 63 M ND1 m.11778G>A 89 68 LHON
M37f 69 F 53 57 No complaints
M28 58 M 4977 bp deletion ND < 1 CPEO, myopathy, glaucoma, hearing loss, hypoventilation
M23 57 F 4977 bp deletion 41 < 1 CPEO/KSS, myopathy, swallowing problems, CMP, EI, PNP
M134 60 F 4977 bp deletion 60 < 1 CPEO, proximal discrete myopathy
M33 66 F 4977 bp deletion 45–50 < 1 CPEO, myopathy
M24 21 F 6 kb deletion ND < 1 CPEO, EI, dyspepsia, dysphagia
M07 42 M 3.5 kb deletion 60–70 < 1 CPEO/KSS, opticopathy, axonal motor polyneuropathy
Age age at muscle biopsy, % sk. muscle mean mtDNA mutation load in skeletal muscle, % MABs mean mtDNA mutation load in mesoangioblasts, DM diabetes
mellitus, EI exercise intolerance, MELAS mitochondrial encephalopathy with lactic acidosis and stroke-like episodes, MIDD maternally inherited diabetes and
deafness, HCM hypertrophic cardiomyopathy, PNP polyneuropathy, CVA cerebrovascular accident, LHON Leber’s Hereditary Optic Neuropathy, CPEO chronic
progressive external ophthalmology, KSS Kearns-Sayre syndrome, CMP cardiomyopathy, ND not determined
aM8 and M20 are siblings and cousins of M1 and M18
bM5 and M6 are siblings
cM9 is mother of M10
dM17 is mother of M11
eM22 is mother of M02
fM34 and M37 are siblings
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described [28] on a FACS ARIA (BD). Alternatively, cells
were stained using the Alkaline phosphatase staining kit
(Stemgent), and AP-positive MABs were collected manu-
ally using a micromanipulator as described previously
[29]. For MAB characterization, FACS analysis of 10,000
cells was performed using PE-labeled CD13, CD44, CD45,
CD34, CD31, and CD56 (Miltenyi Biotech). Depletion of
CD56+ cells was performed using magnetic-activated cell
sorting (MACS) using CD56 microbeads according to the
manufacturers’ protocol (Miltenyi Biotech).
DNA isolation
Genomic and mtDNA from cell pellets and tissues was
isolated using the Wizard Genomic DNA isolation kit
(Promega) according to the manufacturer’s protocol.
Single cells were lysed by adding alkaline lysis buffer
containing 50mM dithiothreitol (DTT) (Pharmacia Bio-
tech) and 200mM NaOH (Sigma), followed by 15-min
incubation at 65 °C.
Genetic analyses of mtDNA mutations
After cell lysis of single cells, the mtDNA mutation load of
the m.3243A>G, m.8363G>A, m.3271 T>C, and 3291 T>C
mutation was analyzed by directly performing PCR I on
the GeneAmp PCR System 9700 (Perkin-Elmer Applied
Biosystems) in a total volume of 50 μl. The PCR mix con-
tained Tricine (20mM pH 4.95 (Sigma)) for neutralization
of the alkaline lysis buffer, 1× PCR buffer, 1 U of Taq
DNA polymerase, 0.06 μM forward primer, 0.3 μM reverse
primer, MgCl2, and 0.1mM dNTP (Pharmacia). First-
round PCR started with 5-min denaturation at 94 °C
followed by 34 cycles (or 38 cycles for single cells) of 1min
92 °C, 45 s at Tm primer (see Additional file 1: Table S1)
and 45 s at 72 °C, followed by 7min at 72 °C. Fifteen mi-
croliters of first-round amplification product was used for
one final amplification cycle containing labeled primer
(Additional file 1: Table S1) using PCR temperatures and
times/cycle as for PCR I. Fifteen microliters of the labeled
second-round PCR product was digested in a total volume
of 50 μl containing 10U restriction enzyme (10 U/ml; Bio-
labs). After digestion, samples were purified using the
innoPREP PCR pure kit (Analytik-Jena) and analyzed by
capillary electrophoresis on an ABI Prism 3730 Genetic
Analyzer followed by GeneScan Analysis 3.7 software
package (Applied Biosystems). Specific details for the de-
tection of each point-mutation (primer sequences, Tm,
MgCl2 concentration, restriction digestion enzyme, ex-
pected sizes mutant and wild-type digested PCR products)
are described in Additional file 1: Table S1. Real-time
quantitative PCR on an ABI 7900HT machine using a
wild-type-specific and m.11778G>A mutation-specific pri-
mer was used for quantification of the m.11778G>A mu-
tation load. After single-cell lysis, 100mM tricine (Sigma)
and water were added to a total volume of 10 μl, of which
2.5 μl was used per PCR reaction. Real-time PCR amplifi-
cation was performed in a 12.5 μl reaction containing 1x
Sensimix Sybr Hi-Rox reagents (Bioline), 375 nM forward
primer (mutant or wild-type), and 375 nM reverse using
the following settings: 10-min denaturation at 95 °C,
followed by 45 cycles of 15 s 95 °C and 1min 67 °C. Semi-
quantitative analysis of large-scale mtDNA deletions was
assessed by long-range PCR amplification of the mtDNA.
Per reaction, 1x GC-buffer, 1 U Phusion Hot Start DNA
polymerase II, 0.1 mM dNTP (Pharmacia), and 0.5 uM
forward primer. PCR started with 30-s denaturation at
98 °C, 32 cycles of 10 s 98 °C, and 8min 15 s 72 °C, followed
by 10min at 72 °C. Subsequent PCR analysis was per-
formed to verify the m.8482_m.13460 deletion of 4977 bp
(nucleotide position based on NC_012920.1). PCR mix con-
tained 1x Amplitaq 360 master mix, 0.6 μM forward pri-
mer, and 0.6 μM reverse primer. PCR started with 5-min
denaturation at 95 °C, 40 cycles of 30 s 95 °C, 30 s 60 °C,
and 1min 72 °C, followed by 5min at 72 °C.
mtDNA copy number analysis
The mtDNA copy number was determined by comparing
the ratio of mtDNA (D-loop) to nuclear DNA (B2M). Per
reaction, 5 ng DNA was amplified in a 12.5 μl reaction
containing 1x Sensimix Sybr Hi-Rox reagents (Bioline)
and 375 nM of forward and reverse primer. Real-time
quantitative amplification was performed on a ABI
7900HT using the following settings: 10min 95 °C, 40 cy-
cles of 15 s 95 °C and 1min 60 °C.
Proliferation capacity
Mesoangioblasts at passage 4 were seeded at a density of
5000/cm2 in mesoangioblast culture medium and passaged
every 3–4 days. At each passage, cell number was assessed
in duplicate using a Fuchs-Rosenthal hemocytometer.
Population doubling level = 3.32 (log viable cells at harvest
− log seeded cells).
Myogenic differentiation
At confluence, myogenic differentiation of mesoangio-
blasts was induced by DMEM supplemented with 2%
horse serum and 1% pen/strep for 10 days. After 5min
3.7% formaldehyde (Sigma-Aldrich) fixation, PBS rinse,
permeabilization in 0.2% Triton in PBS for 30min and 1 h
blocking in 1% BSA (Sigma), cultures were stained with
MF20 antibody (DSHB) 1:10 in 0.05% triton/PBS over-
night at 4 °C. Subsequently, the cells were rinsed three
times with PBS, incubated with GAM-AF488 1:1000 for 1
h, rinsed three times with PBS, and mounted with
DABCO and DAPI in glycerol (Sigma-Aldrich). In vitro
myogenesis was calculated as the number of nuclei in
MF20-positive fibers divided by total number of nuclei per
field. A minimum of 100 nuclei were counted from ≥ 3
randomly chosen fields.
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OXPHOS capacity
Mesoangioblasts were seeded at 20,000 cells/well 1 day prior
to analysis, and the OXPHOS capacity was assessed using
the Seahorse XF Cell Mito Stress Test kit (Agilent) on the
Seahorse XF96 extracellular flux analyzer (Agilent) according
to the manufacturer’s protocol. For the mitochondrial stress
test, the following injections were subsequently used: 1 μM
oligomycin, 0.6 μM carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP), and a combination of 1 μM rote-
none and 1 μM antimycin A.
Statistical analyses
A beta linear regression model was constructed to de-
scribe the myogenic fusion index (%). A hierarchical
model was built, including interactions, allowing for
sex, the age at muscle biopsy, and the mtDNA muta-
tion load in mesoangioblasts (log scale) to be taken
into account. The inference criterion used for com-
paring the models is their ability to predict the ob-
served data, i.e., models are compared directly
through their minimized minus log-likelihood. When
the number of parameters in models differs, they are
penalized by adding the number of estimated parame-
ters, a form of the Akaike information criterion (AIC)
[30]. All statistical analyses presented were performed
using the freely available program R [31] and the
publicly available libraries “gnlm” [32].
Results
Mutation load mtDNA point-mutations in skeletal muscle
and mesoangioblasts
From all mtDNA point-mutation carriers included in
this study, each familial mutation was detected in hair,
blood, and/or urine. A vastus lateralis muscle biopsy
was performed to establish the mtDNA mutation load in
skeletal muscle and isolate MABs. From each subject,
mesoangioblasts were stained with alkaline phosphatase
(AP) and single AP-positive cells were collected using a
micromanipulator. The mtDNA mutation load was ana-
lyzed in a minimal 15 single cells per subject. As shown
in Fig. 1, for the majority of m.3243A>G mutation car-
riers, the mutation load was drastically lower in MABs
compared with skeletal muscle of the same individual.
For the m.8363A>G mutation, this was different. In two
persons (M01, M08) with a skeletal muscle m.8363A>G
load between 41 and 51%, the median MAB mutation load
was 0%, while two other m.8363G>A carriers (M18 and
M20) with a high mutation load in skeletal muscle had a
comparable mutation load in MABs (respectively 89% and
91%). For the two other tRNA Leu mutations, m.3271
T>C and m.3291 T>C, mother and daughter were ana-
lyzed. In both cases, the daughters (M02 and M11) dis-
played a high mutation load in both skeletal muscle and
MABs compared to their mothers. The m.11778G>A mu-
tation was analyzed in MABs and skeletal muscle of two
siblings, M34 and M37. M34 and M37 respectively carried
Fig. 1 mtDNA mutation load per mtDNA point-mutation in single mesoangioblasts. The mtDNA mutation load in single mesoangioblasts in
carriers from 5 different mtDNA point-mutations: a m.3243A>G, b m.3271 T>C, c m.3291 T>C, d m.8363G>A, and e m.11778G>A. Each gray dot
represents the mtDNA mutation load in a single mesoangioblast (> 15 per person were analyzed). Asterisk indicates mean mtDNA mutation load
in skeletal muscle. Dotted black line indicates median mtDNA mutation load analyzed in single mesoangioblasts
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> 90% and 53% of them.11778G>A mutation in muscle.
The distribution of the m.11778G>A mutation load in sin-
gle mesoangioblasts was different, as single M34 MABs
were either > 90% or (near) wild-type, whereas single M37
MABs were more heterogeneous and displayed a
spectrum between 0 and 100%.
Large-scale deletions in skeletal muscle and
mesoangioblasts
For six carriers of a sporadic large-scale deletion in skel-
etal muscle, this deletion was undetectable following
PCR amplification of the complete mtDNA in mesoan-
gioblasts (see Fig. 2). Four of the six patients carried the
most frequently occurring mtDNA deletion of 4977 bp.
The m.8482_13460 breaking points were confirmed in
the muscle tissue of these patients, but were also not de-
tected in the isolated mesoangioblasts (data not shown).
For patients M23 and M33, the large-scale deletion ana-
lysis was also performed in blood, but no large-scale de-
letions were detected as well (data not shown).
Mesoangioblast characterization, proliferation, and
myogenic differentiation capacity
The mesoangioblasts from mtDNA mutation carriers
(M06, M10, M19, M34) proliferated similar to controls
(19 ± 4 population doublings, starting from passage 4).
Mesoangioblasts isolated from subjects between 21 and
63 years old were analyzed, and no correlation between
age at biopsy and proliferation capacity was observed. In
mesoangioblasts with < 10% mtDNA mutation load, re-
petitive analysis of the mutation load at passages 4, 6, 9,
and 15 showed a maximal difference in mutation load of
2.4%. Immunophenotype analysis was performed, and
the MAB cultures were positive for CD13 (99.6 ± 0.5%)
and CD44 (99.4 ± 0.8%), and negative (< 5%) for CD31
(0.6 ± 0.5%), CD34 (1.0 ± 1.9%), and CD45 (0.5 ± 0.5%)
(n = 13) (see Additional file 1: Table S3). When analyzed
at passage 2, two cultures displayed > 5% CD34 expres-
sion, which was lost at passages 5 and 8, respectively. In
addition, analysis of CD56 showed > 5% CD56+ cells in 6
out of 13 cultures. Magnetic activated cell sorting (MACS)
using CD56+ beads demonstrated efficient depletion of
CD56+ cells (< 5%). To assess the myogenic potency of
MABs isolated from mtDNA mutation carriers, MABs
from patients of varying age and with varying mtDNA mu-
tation load were in vitro differentiated in multinucleated
myotubes after culture in myogenic medium. The observed
percentage of multinucleated fibers ranged between 0 and
37.1% (n = 18) (Additional file 1: Table S4). The best linear
regression model included an interaction between age at bi-
opsy and the log mtDNA mutation load in mesoangio-
blasts, as shown in Fig. 3. Analysis of the mtDNA mutation
load after in vitro myogenic differentiation was not signifi-
cantly changed 1.5% ± 1.7% in MAB-derived myotubes
compared with undifferentiated MABs (n = 4).
Mitochondrial OXPHOS capacity and mtDNA copy
number in mesoangioblasts
The mtDNA copy number was determined in all
mtDNA mutation carriers and controls. As shown in
Fig. 4, mesoangioblasts contain on average 148 ± 56
(mean ± S.D.) mtDNA copies per cell. No clear correl-
ation between mesoangioblasts with a high or low mu-
tation load could be observed, nor a correlation
between type of mutation and mtDNA copy number.
Mutations in tRNAleu are known to affect the oxygen
consumption rate. We assessed the oxygen consump-
tion rate in six mesoangioblast cultures of tRNAleu
mutation carriers. Four had no or low mtDNA muta-
tion load (< 10%) (M06, M10, M22, CTRL) and dis-
played normal mitochondrial function (Fig. 5), while
two mesoangioblast cultures with a high > 80% mtDNA
mutation load (M02 and M11) displayed aberrant mito-
chondrial function.
Fig. 2 Semi-quantitative analysis of large-scale mtDNA deletions in mesoangioblasts and skeletal muscle. The 16.5 kb mtDNA was PCR amplified
and analyzed on a 0.7% agarosegel. M, mesoangioblasts; S, skeletal muscle
Tienen et al. Stem Cell Research & Therapy          (2019) 10:405 Page 6 of 10
Discussion
In 11 out of 19 mtDNA point-mutation carriers, the
mean mutation load was more than 50% lower in
mesoangioblasts compared with skeletal muscle. More-
over, the mesoangioblast mutation load was below 10%
in 9 individuals (Fig. 1). This drastic difference in muta-
tion load between mesoangioblasts and skeletal muscle
was observed for all five mutations analyzed, but most
frequently in carriers of the m.3243A>G mutation (7 of
9 cases). Moreover, large-scale deletion(s) were not ob-
served in mesoangioblasts of any of the mtDNA deletion
carriers. At this moment, we cannot exclude that the
mtDNA deletion was present in MABs when residing qui-
escent in the skeletal muscle. The mtDNA mutation may
also be lost during the first proliferation step ex vivo, as
has been reported by Spendiff et al. for satellite cells from
carriers of a large-scale mtDNA deletion. In most of the
eight analyzed patients in that study, the mtDNA deletion
was present in satellite cells, but lost upon satellite cell ac-
tivation and myoblast proliferation [16]. In contrast,
MABs of a number of mtDNA point-mutation carriers in
our study did display a high mtDNA mutation load (see
Fig. 1). The low mtDNA mutation load in MABs of other
point-mutation carriers are therefore unlikely a conse-
quence of preferential expansion of MABs that contain a
low mtDNA mutation load or due to selection against
mutated MABs, although this cannot be fully excluded.
Satellite cell activation has been exploited to effectu-
ate alterations in the mtDNA mutation load in patients
[8, 13, 14, 33]. Based on our findings, mesoangioblasts
Fig. 3 Myogenic potency of mesoangioblasts from mtDNA carriers. The myogenic potential was quantified following 10 days of differentiation in
2% horse serum containing medium and quantification of the myogenic fusion index, namely the number of nuclei (DAPI) in myosin-positive
(MF20) muscle fibers per total number of nuclei per field. a Example image of 10 days differentiated MABs following MF20 immunostaining of
myotubes (green) and DAPI nuclear stain (blue). b Interaction between age at biopsy and the mesoangioblast mtDNA mutation load (irrespective
of type of mtDNA mutation) on the spontaneous myogenic potential of mesoangioblasts, using the best linear regression model obtained and
described by E(Myogenic fusion index) = 0.146 − 0.00155 × age − 0.0394 × ln(MABs) + 0.00056 × age × ln(MABs)
Fig. 4 Mesoangioblast mtDNA copy number. The mean mtDNA copy number per cell line was determined by qPCR analysis of mtDNA D-loop
and nuclear B2M. Per sample, the mean mtDNA copy number ± S.E.M. is shown. The solid line represents the mean mtDNA copy number
calculated from all samples (n = 27), and dashed lines indicate mean ± 2 S.D.
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could also contribute to mtDNA mutation load shifts
upon muscle regeneration after muscle damage. Our
data could also explain why this mtDNA mutation shift
was not observed in all individuals. However, further
research is warranted to assess the mtDNA mutation
load in mesoangioblasts and satellite cells in parallel
in vivo and ex vivo. Due to limitations in sample
amount, this could unfortunately not be done in the
present study. This information may also be of value to
assess whether genetic drift, preferential replication of
the mutated mtDNA in post-mitotic tissues, or other
mechanisms underlie the mtDNA mutation load pat-
tern in mesoangioblasts compared with the load in
skeletal muscle. The low mutation load observed in
MABs from half of the mtDNA point-mutation carriers,
despite their high mutation load in skeletal muscle, is
intriguing and might suggest selection either during
embryonic development or later in life. Also, the distri-
bution of the mtDNA mutation load in MABs is gener-
ally quite homogeneous, either low or high, but not
uniformly distributed. A similar pattern was observed
in myoblasts of m.8344A>G mutation carriers [26].
Possibly, MABs originate early during embryogenesis
when the mtDNA copy number is very low, and solely
wild-type or mutant mtDNA copies are transmitted.
Further investigations, studying MABs during embry-
onic development, are warranted, but require identifica-
tion of a specific MABs marker.
Mesoangioblasts are suitable as cell therapy medicinal
product, and systemic intra-arterial delivery of allogeneic
mesoangioblasts has been applied in a clinical study with
DMD patients [25]. The natural appearance of mtDNA-
mutation-free mesoangioblasts in more than half of the
mtDNA mutation carriers offers the possibility of using
mesoangioblasts for autologous stem cell therapy, which
would circumvent adverse reactions to the transplant
and exclude the use of immunosuppressive agents that
are required for allogeneic transplantation. To this end,
we assessed characteristics important for a cell therapy
medicinal product, for MABs with low or absent muta-
tion loads, derived from patients.
The proliferation capacity of these MABs is comparable
to MABs derived from healthy individuals and DMD pa-
tients [22, 34]. Sampaolesi et al. demonstrated that a dog
model of DMD clinically improved after systemic intra-
arterial delivery of 5 × 10E7 MABs/kg [24]. For a 75-kg
adult, ~ 3.8 × 10E9 MABs would be required. MAB isola-
tion from a ~ 200-mg skeletal muscle biopsy would suffice
to reach this target dose within 15 population doublings,
thereby preserving proliferation capacity upon infusion.
Immunophenotype analysis of the MABs verified that they
were positive for CD13 and CD44 [22]. At early passage,
such as p2, expression of (immature) endothelium markers
CD31 and CD34, characteristic for pericytes, was observed,
a trait lost during in vitro expansion [35]. Also, CD56+ sat-
ellite cells were also observed at early passages of some cul-
tures. Since satellite cells cannot migrate from the
bloodstream to the muscles, depletion of these cells is war-
ranted for development of an intra-arterial delivery and can
be successfully performed by magnetic-activated cell sorting
using CD56 microbeads. MABs spontaneously differenti-
ated into myotubes in vitro with varying efficiency (up to
37.1%). Similar to the results reported for MABs from
healthy individuals and DMD patients [25, 34]. Statistical
analysis of MAB myogenic capacity in relation to their mu-
tation load and age at muscle biopsy demonstrated an
interaction between the age and mutation load (Fig. 3),
which confirms the negative impact aging has on the myo-
genic capacity of wild-type MABs [36]. All analyzed MABs
displayed a normal mitochondrial OXPHOS capacity, at
the exception of M2 and M11 MABs with a mtDNA muta-
tion load of more than 80% that displayed deficient
OXPHOS capacity. The mean mtDNA copy number per
mesoangioblast is 148 ± 56, which is comparable to wild-
type. Five cell lines displayed a mtDNA copy number
higher than the mean ± 2 S.D., which cannot be directly re-
lated to their mutation or mutation load.
Conclusion
Taken together, our data demonstrates that mtDNA-
mutation-free MABs can be obtained from more than
half of the patients. Their proliferation, myogenic differ-
entiation capacity, and mitochondrial function are com-
parable with wild-type mesoangioblasts. This makes
them good candidates for autologous transplantation to
induce muscle regeneration, compatible with the shift of
mtDNA mutation load due to eccentric/resistance exer-
cise [8, 33]. As regular exercise is challenging for this
Fig. 5 Mitochondrial function. Mitochondrial respiration in MABs of
tRNAleu mutation carriers was determined by measuring the oxygen
consumption rate (OCR) in a Seahorse XF96 analyzer during
treatment with oligomycin (oligo), FCCP and Antimycin/Rotenone
(ant/rot), and corrected for cell number. Per cell line, 8 replicates
were included; mean OCR ± S.D. is shown in figure
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patient group because of their disease status and lactate
increase upon exercise, muscle regeneration by intra-
arterial injection of mtDNA-mutation-free autologous
mesoangioblasts could become a good alternative. In
order to enable mesoangioblasts migration from the
bloodstream to the muscles in this patient group, skel-
etal muscle inflammation and subsequent MABs migra-
tion can potentially be effectuated by a bout of eccentric
exercise [37–39].
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